-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5

Benzinga·08/17/2026 13:41:11
Listen to the news
Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to $5.